Innovative approaches in snakebite treatment: the need for precision antivenoms and next-generation diagnostics

Background: Snakebite envenomation Snakebite envenomation is a major public health problem, affecting an estimated 1.8–2.7 million people annually, predominantly in low- and middle-income countries. Despite its classification as a neglected tropical disease by the World Health Organization, snakebite envenomation continues to cause substantial morbidity and mortality, driven in part by limited access to effective antivenoms, delays in treatment, and the lack of widely available rapid diagnostic tools. The marked biological complexity and geographic variability of snake venom composition further complicate clinical management, underscoring the need for innovative and context-appropriate approaches to improve both therapeutic effectiveness and diagnostic accuracy. This review examines recent advancements in regionally informed antivenom strategies and next-generation diagnostic technologies, emphasizing their necessity for achieving more precise, timely, and context-appropriate snakebite management. Methods: This review adopts a structured, critical narrative approach, synthesizing peer-reviewed literature and global health reports to evaluate recent innovations in antivenom development and snakebite diagnostics. Literature was identified using PubMed, Web of Science, and Scopus, with emphasis placed on studies published from 2010 onward, reflecting the period of rapid advances in venom omics, recombinant antivenoms, and diagnostic technologies. Searches were focused on terms directly relevant to the review's analytical scope, including antivenom development, venom proteomics, transcriptomics, and snakebite diagnostics. Rather than aiming for exhaustive coverage, studies were prioritized based on their relevance to therapeutic effectiveness, translational feasibility, scalability, and accessibility in snakebite-endemic settings. Findings were synthesized comparatively to identify key advances, persistent limitations, and barriers to clinical implementation. Findings: Recent advances in antivenom research include the development of recombinant antibody platforms, immunoinformatics-guided design strategies, synthetic biology approaches, and the characterization of endogenous venom resistance mechanisms, all of which have contributed to improved understanding of how specificity and immunogenicity might be optimized beyond conventional antivenoms. At the same time, progress in diagnostic research, particularly involving lateral flow–based immunoassays and multi-omic venom profiling, has highlighted potential pathways for improving venom or toxin identification and supporting more informed clinical decision making. However, translation of these scientific advances into routine clinical practice remains limited. Persistent challenges related to large-scale manufacturing, regulatory approval, affordability, and implementation within resource-constrained health systems continue to restrict the real-world impact of next-generation antivenoms and diagnostics in snakebite-endemic regions. Conclusion: Future progress in snakebite envenomation management will depend on coordinated advances across antivenom development, diagnostic innovation, and supportive global health policy frameworks. Region-informed antivenom strategies, enabled by venom profiling and supported by scalable and modular production models, together with appropriately validated rapid diagnostic tools, represent a plausible pathway toward improving treatment effectiveness and access. Nevertheless, achieving meaningful reductions in morbidity and mortality will require sustained interdisciplinary collaboration and explicit attention to translational, regulatory, and health system constraints, ensuring that scientific innovation is matched by practical feasibility and equitable implementation in high-burden settings.